Brown Advisory Inc. bought a new position in shares of Fluidigm Co. (NASDAQ:FLDM) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,287 shares of the medical research company’s stock, valued at approximately $115,000.

Other institutional investors have also bought and sold shares of the company. Quantamental Technologies LLC acquired a new stake in shares of Fluidigm in the fourth quarter valued at about $61,000. United Services Automobile Association acquired a new stake in shares of Fluidigm in the fourth quarter valued at about $102,000. Rhumbline Advisers grew its position in shares of Fluidigm by 42.9% in the fourth quarter. Rhumbline Advisers now owns 34,489 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 10,358 shares during the last quarter. Chicago Equity Partners LLC acquired a new stake in shares of Fluidigm in the fourth quarter valued at about $313,000. Finally, Monarch Partners Asset Management LLC acquired a new stake in shares of Fluidigm in the fourth quarter valued at about $317,000.

Several equities research analysts have recently issued reports on FLDM shares. Janney Montgomery Scott raised Fluidigm from a “neutral” rating to a “buy” rating in a research report on Thursday, January 3rd. BidaskClub raised Fluidigm from a “hold” rating to a “buy” rating in a research report on Thursday, December 27th. ValuEngine raised Fluidigm from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. BTIG Research started coverage on Fluidigm in a research report on Wednesday, March 13th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Zacks Investment Research downgraded Fluidigm from a “buy” rating to a “hold” rating in a research report on Tuesday, January 1st. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.00.

Shares of FLDM opened at $13.10 on Friday. The company has a debt-to-equity ratio of 2.39, a current ratio of 3.38 and a quick ratio of 3.04. Fluidigm Co. has a 12 month low of $4.65 and a 12 month high of $14.90.

Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings results on Thursday, February 7th. The medical research company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. The firm had revenue of $32.33 million during the quarter, compared to analysts’ expectations of $30.55 million. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 71.42%. Equities analysts forecast that Fluidigm Co. will post -0.58 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Brown Advisory Inc. Invests $115,000 in Fluidigm Co. (FLDM) Stock” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/brown-advisory-inc-invests-115000-in-fluidigm-co-fldm-stock/2925603.html.

Fluidigm Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

See Also: How to Use the New Google Finance Tool

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.